Intralipid (Soya Oil, Purified)

Soya Oil in Intralipid is delivered as triglyceride particles surrounded by phospholipid micelles. After infusion, lipases hydrolyze the triglycerides into free fatty acids and glycerol, which are then utilized by cells for energy production and membrane synthesis.

The dose of Intralipid is individualized by the prescribing clinician based on the patient’s caloric needs, lipid tolerance, and laboratory parameters such as triglyceride levels. No fixed regimen is provided here.

The safety of Intralipid in pregnancy or lactation has not been definitively established. Use should be considered only if the potential benefit justifies any potential risk, and decisions are made by the treating physician.

To order Intralipid, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed), and import documentation.

Intralipid is a soybean‑oil based lipid emulsion, offering a balanced profile of essential fatty acids. Compared with alternative emulsions that may use fish oil or medium‑chain triglycerides, Intralipid provides a traditional fatty acid composition suitable for most parenteral nutrition protocols, though specific clinical needs may guide the choice of formulation.

Intralipid should be stored at 2‑8 °C, kept refrigerated, protected from light, and must not be frozen or shaken. Before administration, the emulsion should be inspected for any signs of separation or discoloration.

Intralipid is administered intravenously as an emulsion, typically infused through a central or peripheral line under aseptic conditions. The infusion rate is set by the clinician according to the patient’s nutritional requirements and tolerance.

Serious risks include fat overload syndrome, pancreatitis, severe allergic reactions such as anaphylaxis, pulmonary embolism, and hepatic dysfunction. Patients should be monitored closely for signs of these complications during and after infusion.

Intralipid is contraindicated in patients with known hypersensitivity to soy or soy oil, those with severe lipid metabolism disorders, active pancreatitis, or uncontrolled hypertriglyceridemia. Clinicians should assess each patient’s medical history before initiating therapy.